152 related articles for article (PubMed ID: 37196766)
21. Making Protein Degradation Visible: Discovery of Theranostic PROTACs for Detecting and Degrading NAMPT.
Cheng J; He S; Xu J; Huang M; Dong G; Sheng C
J Med Chem; 2022 Dec; 65(23):15725-15737. PubMed ID: 36442664
[TBL] [Abstract][Full Text] [Related]
22. Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity.
Sinatra L; Yang J; Schliehe-Diecks J; Dienstbier N; Vogt M; Gebing P; Bachmann LM; Sönnichsen M; Lenz T; Stühler K; Schöler A; Borkhardt A; Bhatia S; Hansen FK
J Med Chem; 2022 Dec; 65(24):16860-16878. PubMed ID: 36473103
[TBL] [Abstract][Full Text] [Related]
23. Spatial regulation of signaling by the coordinated action of the protein tyrosine kinases MET and FER.
Zhang J; Wang Z; Zhang S; Chen Y; Xiong X; Li X; Tonks NK; Fan G
Cell Signal; 2018 Oct; 50():100-110. PubMed ID: 29920310
[TBL] [Abstract][Full Text] [Related]
24. Targeting androgen receptor degradation with PROTACs from bench to bedside.
Jia X; Han X
Biomed Pharmacother; 2023 Feb; 158():114112. PubMed ID: 36508999
[TBL] [Abstract][Full Text] [Related]
25. FER-mediated phosphorylation and PIK3R2 recruitment on IRS4 promotes AKT activation and tumorigenesis in ovarian cancer cells.
Zhang Y; Xiong X; Zhu Q; Zhang J; Chen S; Wang Y; Cao J; Chen L; Hou L; Zhao X; Hao P; Chen J; Zhuang M; Li D; Fan G
Elife; 2022 May; 11():. PubMed ID: 35550247
[TBL] [Abstract][Full Text] [Related]
26. Drug delivery challenges and formulation aspects of proteolysis targeting chimera (PROTACs).
Saraswat AL; Vartak R; Hegazy R; Patel A; Patel K
Drug Discov Today; 2023 Jan; 28(1):103387. PubMed ID: 36184017
[TBL] [Abstract][Full Text] [Related]
27. PROTACS: A technology with a gold rush-like atmosphere.
Wang YW; Lan L; Wang M; Zhang JY; Gao YH; Shi L; Sun LP
Eur J Med Chem; 2023 Feb; 247():115037. PubMed ID: 36566716
[TBL] [Abstract][Full Text] [Related]
28. The application of PROTAC in HDAC.
Chen S; Zheng Y; Liang B; Yin Y; Yao J; Wang Q; Liu Y; Neamati N
Eur J Med Chem; 2023 Nov; 260():115746. PubMed ID: 37607440
[TBL] [Abstract][Full Text] [Related]
29. Design and synthesis of proteolysis-targeting chimeras (PROTACs) as degraders of glutathione peroxidase 4.
Cai M; Ma F; Hu C; Li H; Cao F; Li Y; Dong J; Qin JJ
Bioorg Med Chem; 2023 Jul; 90():117352. PubMed ID: 37257255
[TBL] [Abstract][Full Text] [Related]
30. PROTAC-biomacromolecule conjugates for precise protein degradation in cancer therapy: A review.
Wang C; Zhang Y; Yu W; Xu J; Xing D
Int J Biol Macromol; 2024 Mar; 261(Pt 2):129864. PubMed ID: 38302015
[TBL] [Abstract][Full Text] [Related]
31. CRBN ligand expansion for hematopoietic prostaglandin D
Osawa H; Kurohara T; Ito T; Shibata N; Demizu Y
Bioorg Med Chem; 2023 Apr; 84():117259. PubMed ID: 37018877
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and biological evaluation of KRAS
Zhang X; Zhao T; Sun M; Li P; Lai M; Xie L; Chen J; Ding J; Xie H; Zhou J; Zhang H
Bioorg Med Chem; 2023 Jan; 78():117153. PubMed ID: 36621179
[TBL] [Abstract][Full Text] [Related]
33. Discovery of a miniaturized PROTAC with potent activity and high selectivity.
Gong L; Li R; Gong J; Ning X; Sun J; Ma Q; Zhu C; Yang Y; Lin K; Li Y; Zhang Q; Li T; Lin Z
Bioorg Chem; 2023 Jul; 136():106556. PubMed ID: 37105002
[TBL] [Abstract][Full Text] [Related]
34. Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion.
Sood AK; Coffin JE; Schneider GB; Fletcher MS; DeYoung BR; Gruman LM; Gershenson DM; Schaller MD; Hendrix MJ
Am J Pathol; 2004 Oct; 165(4):1087-95. PubMed ID: 15466376
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and biological evaluation of the tumor hypoxia-activated PROTACs bearing caged CRBN E3 ligase ligands.
Cheng W; Li S; Han S; Miao R; Wang S; Liu C; Wei H; Tian X; Zhang X
Bioorg Med Chem; 2023 Mar; 82():117237. PubMed ID: 36906965
[TBL] [Abstract][Full Text] [Related]
36. The Fer tyrosine kinase regulates an axon retraction response to Semaphorin 3A in dorsal root ganglion neurons.
Shapovalova Z; Tabunshchyk K; Greer PA
BMC Dev Biol; 2007 Nov; 7():133. PubMed ID: 18053124
[TBL] [Abstract][Full Text] [Related]
37. Folate-PEG-PROTAC Micelles for Enhancing Tumor-Specific Targeting Proteolysis In Vivo.
Ma J; Fang L; Sun Z; Li M; Fan T; Xiang G; Ma X
Adv Healthc Mater; 2024 Apr; ():e2400109. PubMed ID: 38676445
[TBL] [Abstract][Full Text] [Related]
38. Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity.
Chen C; Yang Y; Wang Z; Li H; Dong C; Zhang X
J Med Chem; 2023 Jul; 66(13):8428-8440. PubMed ID: 37317568
[TBL] [Abstract][Full Text] [Related]
39. Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL.
Lai AC; Toure M; Hellerschmied D; Salami J; Jaime-Figueroa S; Ko E; Hines J; Crews CM
Angew Chem Int Ed Engl; 2016 Jan; 55(2):807-10. PubMed ID: 26593377
[TBL] [Abstract][Full Text] [Related]
40. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.
Noblejas-López MDM; Nieto-Jimenez C; Burgos M; Gómez-Juárez M; Montero JC; Esparís-Ogando A; Pandiella A; Galán-Moya EM; Ocaña A
J Exp Clin Cancer Res; 2019 Aug; 38(1):383. PubMed ID: 31470872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
